Mavenir Acquires Telestax to Enhance Its Business Messaging and Customer Engagement Platform with CPaaS
25.8.2021 14:15:00 EEST | Business Wire | Press release
Mavenir, the global leader in mobile messaging and business messaging monetization solutions for service providers, announced today that it has acquired Telestax Inc., a leading global Communications Platform as a Service (CPaaS) enablement and application provider to the communications industry. This acquisition enhances Mavenir Engage, Mavenir’s omni-channel messaging monetization and customer engagement offerings by:
- enabling service providers with new agile, nimble SaaS service models to better compete in the new digital economy
- delivering specialization, flexibility, and simplicity to meet the needs of businesses of all sizes across a broad spectrum of industry verticals
- providing service innovation and feature velocity with easy-to-consume APIs and business-critical applications
“Communication Platforms are becoming a key differentiator for service providers,” said Pardeep Kohli, President and CEO, Mavenir. “They will unlock enterprise value in 5G with API enablement for different verticals such as IoT, Smart Cities, Automotive and provide turnkey applications for logistics, fleet management, AI/ML chatbots, voice biometrics verification, immersive commerce/entertainment and many other use cases.”
“The early definition of CPaaS in terms of PSTN connectivity has been augmented to include a much broader range of services. Vendors that provide the full communication service stack – including the API layer and network infrastructure – have a competitive advantage from those whose strategy primarily focuses on the API layer and relies on partnerships to provide access to the network layer,”1 said Raúl Castañón-Martínez, Sr. Analyst, Workforce Productivity and Collaboration at 451 Research, a division of S&P Global Market Intelligence. According to 451 Research's Workforce Productivity & Collaboration 2021 CPaaS Market Monitor, total market revenue increased by well over 40% to $6.5bn in 2020, and will account for roughly $21bn in 2025, a CAGR of 26%.
“CPaaS is the key enabling technology for our Mavenir Engage service to position Communications Service Providers (CSPs) at the forefront of the digital engagement landscape,” said Ian Maclean, SVP/GM Cloud Services at Mavenir, “With this acquisition, Mavenir is lowering the barrier of entry and democratizing business messaging for businesses of all sizes to implement conversational commerce experiences.”
Mavenir Engage is Mavenir’s cloud-based messaging monetization and customer engagement offering that provides CSPs, systems integrators and channel partners with RCS Business Messaging (RBM), messaging monetization capabilities, chatbots, campaign management, and access to different messaging ecosystems—such as Google RCS Business Messaging.
Clark Peterson, Chairman, Cloud Communications Alliance, said: “Telestax has been a key partner to help drive the transformation of the CPaaS industry. Being part of the Mavenir family brings the breadth of portfolio to add new capabilities and further advance innovative customer offerings in Cloud Communications.”
Mavenir empowers service providers to give enterprises the ability to optimize workflows and customize business applications to better engage customers and employees. Eliminating complexity for their employees, increasing productivity and, most importantly, delighting their customers with a better customer experience.
Jean Deruelle, co-founder and CTO, Telestax, said: “From our roots as an Open-Source communications disruptor that defined the CPaaS Enablement Market with the Restcomm API framework, we are incredibly excited to join forces and combine our capabilities with Mavenir’s extensive 5G and omni-channel messaging portfolio in the next step of our journey to keep helping carriers globally define the future of business communications.”
About Mavenir
Mavenir is building the future of networks and pioneering advanced technology, focusing on the vision of a single, software-based automated network that runs on any cloud. As the industry’s only end-to-end, cloud-native network software provider, Mavenir is focused on transforming the way the world connects, accelerating software network transformation for 250+ Communications Service Providers in over 120 countries, which serve more than 50% of the world’s subscribers. www.mavenir.com
_____________________
1 451 Research, “Communications Platforms as a Service Market Guide 2021”
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210825005157/en/
Contact information
Mavenir PR Contact:
Maryvonne Tubb
Mavenir
PR@mavenir.com
Casey Bush
GlobalResultsPR (US)
mavenir@globalresultspr.com
Kevin Taylor
GlobalResultsPR (EMEA)
mavenir@globalresultspr.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom